Oncolytics Biotech Inc. Appoints Andrew Aromando as New Chief Business Officer
- Oncolytics Biotech Inc. appointed Andrew Aromando as Chief Business Officer, effective June 30, 2025, enhancing its strategic development.
- Aromando will oversee global business development and leverage clinical data to improve the marketability of pelareorep.
- His extensive experience in oncology biopharma supports Oncolytics' commitment to innovation and growth in the oncology market.
Oncolytics Biotech Inc. Appoints Andrew Aromando as Chief Business Officer
Oncolytics Biotech Inc. takes a significant step forward in its strategic development by appointing Andrew Aromando as its new Chief Business Officer, effective June 30, 2025. Aromando arrives with a wealth of experience, bringing over three decades in the life sciences sector, which positions him well to lead Oncolytics in enhancing its business operations. His most recent role as Chief Operating Officer at Ambrx Biopharma saw him play a pivotal part in the company’s $2 billion acquisition by Johnson & Johnson. This background not only underscores his capability in managing corporate growth but also highlights his expertise in navigating high-stakes transactions within the biopharmaceutical industry.
In his new position at Oncolytics, Aromando will be responsible for overseeing global business development, focusing on corporate, clinical, and regulatory strategies. A notable aspect of his role will involve leveraging Oncolytics' extensive clinical data to enhance the value and marketability of its lead product, pelareorep. This innovative therapy has shown promise in targeting multiple tumor types, including pancreatic, breast, and anal cancers. Aromando’s extensive experience in oncology-focused biopharma will be critical as Oncolytics seeks to advance its clinical programs, aiming to maximize the potential of its therapies in a competitive landscape.
Aromando's appointment aligns with Oncolytics' ongoing commitment to innovation and leadership in oncology. With more than 20 years in C-level roles at various biopharmaceutical companies and global service providers, he emphasizes strategic planning, corporate development, portfolio optimization, and product commercialization. His academic credentials, including a Bachelor's degree from The College of New Jersey and a Master's degree from Rutgers University, further enhance his profile as a leader in the industry. This strategic move signals Oncolytics' determination to strengthen its position in the oncology market and harness its innovative capabilities for future growth.
In addition to Aromando's appointment, Oncolytics continues to focus on advancing its clinical trials and expanding its research initiatives. The company is committed to exploring new therapeutic avenues, ensuring that its offerings remain at the forefront of oncology treatment options. As the industry evolves, Oncolytics aims to leverage Aromando’s expertise to navigate challenges and capitalize on new opportunities.
Overall, the strategic hiring of Andrew Aromando marks a pivotal moment for Oncolytics Biotech Inc., reinforcing its dedication to developing groundbreaking therapies in the fight against cancer while positioning the company for future success.